Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay Save
Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.
Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.